Olav Bergheim
Founder & MD @ Fjord Ventures
Laguna Hills, United States
Olav Bergheim is a seed investor at Fjord Ventures in Laguna Hills focused on Medical and Wellness. Olav Bergheim has over 30 years of experience in creating and managing life science companies. He is a founder of Sonendo, Inc., in addition to several other successful life science companies including Volcano Corporation, 3F Therapeutics (acquired by Medtronic), Glaukos Corporation, Lonestar Heart Inc., Prelude Corporation and Metronom Health,Inc. Mr. Bergheim is also the founder of Fjord Ventures LLC, a life science accelerator located in Laguna Hills, California, where Sonendo was created. Mr. Bergheim was the chairman of Vessix Vascular, Inc. (acquired by Boston Scientific). Prior to starting Fjord Ventures, he spent 10 years at Domain Associates as a company creator and general partner. Prior to Domain, Mr. Bergheim spent 18 years with Baxter Healthcare at US and international locations, where he held various leadership and operating roles. Mr. Bergheim was a Corporate VP of Baxter as well as President of Baxter Germany, President of Baxter’s Cardiovascular Group (now Edwards Life Sciences) and General Manager of the Nordic area.
- Total investments:
- 3
- Last investment:
- Lead investor:
- 0%
Last updated:
For AI agents: llms.txt
Industries Olav Bergheim invests in
Stages Olav Bergheim invests in
Countries Olav Bergheim invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Medical 1 (33%)
- Wellness 1 (33%)
- Health Care 1 (33%)
- Manufacturing 1 (33%)
- Industrial Automation 1 (33%)
Stage
- Seed 1 (33%)
- Series D 1 (33%)
- Series E 1 (33%)
Country
- Norway 1 (33%)
- United States 1 (33%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
OTee
|
OTee specializes in the development of industrial automation software, offering a comprehensive solution for the setup, testing, and safe operation of operational facilities in real time. The company's platform is designed to provide automation engineers with a secure, scalable, and user-friendly environment. By utilizing OTee's software,businesses can streamline their operations, allowing them to concentrate on their core tasks while enhancing the performance of their facilities. | $1.4M / Seed / Feb 05, 2024 | |
Glaukos
|
Glaukos Corporation is an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures designed to transform the treatment of glaucoma, one of the world’s leading causes of blindness. They have pioneered Micro-Invasive Glaucoma Surgery, or MIGS, in order to revolutionize thetraditional glaucoma treatment and management paradigm.They launched the iStent®, their first MIGS device, in the United States in 2012. They are leveraging their platform technology to build a comprehensive and proprietary portfolio of injectable micro-scale therapies designed to address the complete range of glaucoma disease states and progression. They believe the iStent® is the smallest medical device ever approved by the Food and Drug Administration, or FDA, measuring 1.0 mm long and 0.33 mm wide.In June 2015, they completed an initial public offering and their shares are now traded on the New York Stock Exchange under the ticker symbol “GKOS”. The company was founded in 1998 and is based in San Clemente, California. | $29.5M / Series E / Feb 02, 2011 | |
|
Glaukos
|
Glaukos Corporation is an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures designed to transform the treatment of glaucoma, one of the world’s leading causes of blindness. They have pioneered Micro-Invasive Glaucoma Surgery, or MIGS, in order to revolutionize thetraditional glaucoma treatment and management paradigm.They launched the iStent®, their first MIGS device, in the United States in 2012. They are leveraging their platform technology to build a comprehensive and proprietary portfolio of injectable micro-scale therapies designed to address the complete range of glaucoma disease states and progression. They believe the iStent® is the smallest medical device ever approved by the Food and Drug Administration, or FDA, measuring 1.0 mm long and 0.33 mm wide.In June 2015, they completed an initial public offering and their shares are now traded on the New York Stock Exchange under the ticker symbol “GKOS”. The company was founded in 1998 and is based in San Clemente, California. | $35M / Series D / Aug 29, 2008 |
Co-Investors
About Fjord Ventures
Fjord Ventures LLC was founded in mid-2005 and is committed to providing strategic vision and operational excellence to emerging life sciences companies. The Firm is based in Orange County, California.
Fjord Ventures Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Hugh A.Neuharth
Chief Financial Officer
|
|||
|
Kristen Apgar
Director, Operations & Corporate Administration
|
|||
|
Olav Bergheim
Founder & MD
|
|||
|
Tyler Kibbee
Associate
|
|||
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Olav Bergheim invest in?
Olav Bergheim invests primarily in Medical, Wellness and Health Care startups, most often at Seed and Series D stage. Most of the 3 investments tracked by Shizune back companies in Norway. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Olav Bergheim?
For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Olav Bergheim last invest?
The most recent investment recorded for Olav Bergheim closed in Feb 2024. Shizune tracks 3 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
